Research Peptide Fundamentals research peptides

The short version

This desk covers four research peptides that share one thing: they have more published clinical or preclinical data than most. Two of them — tesamorelin and semaglutide — are FDA-approved drugs with phase-3 trials involving hundreds to tens of thousands of people. One, thymosin alpha-1, is approved as a drug in dozens of other countries but not the United States, and just had a major phase-3 trial come back negative. The fourth, PT-141 (bremelanotide), is FDA-approved for one specific sexual-health indication in premenopausal women only.

A peptide is a short chain of amino acids — the building blocks of proteins, but far smaller. These four work through very different mechanisms: stimulating a growth-hormone pathway, mimicking an appetite hormone, modulating immune-cell behavior, and activating central brain receptors. What they have in common is that someone has run reasonably large, controlled studies on them and written down the results in peer-reviewed journals.

This site reports those results, as those studies reported them, with species noted and caveats intact. It does not sell anything, does not recommend doses, and does not give medical advice.

The peptides with the most clinical and preclinical data

The frame for this desk is deliberate. Hundreds of peptides are sold as research chemicals; most have one rodent study and a forum thread to their name. The four covered here are chosen because the evidence base is meaningfully larger — not without limits, but large enough to read carefully.

• Tesamorelin is the lead. As the only FDA-approved peptide on this desk for its core indication, it has the cleanest regulatory record. Its approval is narrow — HIV-associated lipodystrophy — and a 2026 meta-analysis of five RCTs confirmed the visceral-fat effects ^[1]. Every other use is off-label and investigational ^[7].
• Semaglutide has the most large-trial human data, with landmark studies in weight management ^[11], cardiovascular outcomes ^[10], and kidney disease ^[9]. That volume of evidence also means its adverse-effect profile is well characterized ^[12].
• Thymosin Alpha-1 sits in a harder-to-read literature: approved abroad, trial history spanning decades, and a 2025 phase-3 sepsis RCT (TESTS, n=1,106) that found no mortality benefit ^[13]. The evidence is real — and mixed.
• PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women ^[22]. Its mechanism — central melanocortin-receptor activation — is distinct from vascular-acting compounds. Phase-3 data exist ^[20], and the side-effect profile is frank and should be read ^[21].

Compare these peptides side by side in one table.

What are research peptides?

A protein is a long, folded chain of amino acids. A peptide is a shorter chain of the same building blocks, sometimes only a few links long. Because they are small and specific, peptides can bind particular receptors on cell surfaces with high selectivity, which is exactly what makes them interesting as drug candidates — and what made these four worth running clinical trials on.

When a peptide is described as a 'research peptide' or 'research chemical,' it occupies a category that ranges from well-characterized drugs to compounds with almost no human data. This desk covers the end of that spectrum with actual clinical data, but that does not dissolve the distinction: research-grade material sold for laboratory use lacks the quality controls, purity verification, and potency oversight of an approved pharmaceutical product. That gap matters and is noted on each compound page.

How this desk reads the literature

Peptides Foundation is a literature digest. Every factual claim on these pages is tied to a specific peer-reviewed study, regulatory document, or NIH monograph, cited by number. Where evidence is strong — a pre-registered phase-3 RCT with a pre-specified primary endpoint — we say so. Where it is weak — a single retrospective cohort, a rodent model, an open-label pilot — we say that too.

We do not average over the literature. A compound can have encouraging early data and a null phase-3 trial, and both are in the record. The aim is accurate map-making: where is the ground solid, where is it soft, where is there no ground at all yet. Read the references if you want the primary sources; read About if you want to understand the editorial standards.